The BioHub - by Avetix

Today, we're joined by Dr. Tatiana Novobrantseva, the Chief Scientific Officer at NextPoint Therapeutics, a clinical-stage biotech company pioneering precision immuno-oncology therapies targeting the novel HHLA2 (B7-H7) pathway. Tatiana brings over two decades of expertise in immunology, cancer, immuno-oncology, autoimmunity, and fibrosis. She co-founded Verseau Therapeutics in 2017, serving a...

Welcome back to another episode of The BioHub, we weredelighted to welcome on Nick Manusos, the CEO of Kenai Therapeutics, a pioneering biotech company developing neuron replacement therapies for neurological disorders. Nick’s journey spans decades of innovation and leadership—from senior roles at global pharma giants like Baxter, Takeda, and Abbott, to founding and leading cutting-edge startups l...

Today’s guest is someone who’s seen biotech from both sidesof the table—first as an investor, and now as a builder. I’m joined by Punit Dhillon, CEO of Skye Bioscience, wherehe’s leading one of the most exciting stories in metabolic health. Punit started Skye as employee number one and has sincebuilt it into a clinical-stage company with one first-in-class programs and backing from major life scie...

We were delighted to welcome Paula Soteropoulos, Chairman of the Board at Ensoma and Venture Partner at 5am Ventures, onto The BioHub. Paula is a seasoned leader whose career spans some of the most influential companies in the industry and she's played a pivotal role in shaping the biotechlandscape over the past few decades She began her journey at Genzyme, where she spent nearly two decades h...

Welcome back to another episode of The BioHub, we were thrilled to welcome on Nolan Townsend, CEO of Lexeo Therapeutics. Nolan has been at the helm of Lexeo since January 2020, leading a clinical-stage genetic medicine company aiming to transform treatment for genetically-defined cardiovascular diseases and APOE4-associated Alzheimer’s disease. Under his leadership, Lexeo has built a pipeline of t...

Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry. I’m joined by Dr. Stefan Lutz, SVP of Research at Codexis—a leader in enzyme engineering and the force behind some of the most exciting advancements in RNA manufacturing. Stefan’s journey spans academia and industry, from chairing the Chemistry Department at Emory University to now driving...

Thanks for tuning into another episode of The BioHub, we were delighted to welcome on Micah Mackison who serves as the Chief Executive Officer of Vico Therapeutics, a company blazing trails in genetic neurology with RNA-based medicines. Since taking the helm in August 2022, Micah has been leading Vico’s drive to translate novel oligonucleotide RNA-modulating therapies from the lab into clinical tr...

Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry. Today I’m joined by Andy Parker, the CEO of Step Pharma. Andy has spent over two decades in biotech and pharma,holding senior leadership roles at companies like AstraZeneca, Shire and Zealand Pharma and even spending time on the VC side at Eclosion. Since 2019, he’s been leading Step Pharma...

We were delighted to welcome Robert Ross, Chief Executive Officer at Clasp Therapeutics, onto The BioHub. Clasp Therapeutics are a pioneering biotech company spearheading the next generation of T-cell engager therapies. Founded in 2024 and backed by a successful $150 million Series A round with top tier investors, Clasp stands out for its novel approach in delivering off-the-shelf, bispecific T‐ce...

Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry. On this episode we were joined by Kristof Vercruysse, CEO of TargED Biopharmaceuticals, an Utrecht-based biotech who're developing a novel Targeted Enzyme Delivery approach to Thrombolysis. On this episode, we discuss the current standard of care in indications such as TTP & Acute I...

I am conscious that I redo the ontro here - Please excuse Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry. I’m joined by Aaron Kantoff — Co-Founder and Managing Partner at Scion Life Sciences. Aaron helped build the therapeutics group at Apple Tree Partners from scratch, co-founding 11 companies along the way. After leaving Apple tree, Aa...

Today, we’re delighted to welcome Alison Finger, MBA, the Chief Operating Officer at Vicero Bio—a preclinical-stage biotech company pioneering VINCOBODY therapies, a next-generation nanobody platform being developed to tackle immune-mediated diseases and cancer. Since stepping into the COO role in September 2023, Alison has been at the helm of Vicero’s business operations, steering strategic and f...

Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry. I’m joined by Rick Winningham, Chairman and CEO of Theravance Biopharma. Rick has led Theravance since its spin-out from Innoviva in 2014, after serving as CEO of Innoviva and holding senior leadership roles at Bristol Myers Squibb. He’s also been a driving force in industry advocacy, chair...

Welcome back to another episoe of The Bio Hub, we were delighted to be joined by Dr. Devyn Smith, a widely respected executive and thought leader in the field of cell and gene therapy, with a career that spans both global pharmaceutical giants and pioneering biotech startups. Devyn is currently the Chief Executive Officer of Arbor Biotechnologies, a company at the forefront of next-generation gene...

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. I’m joined by Gerardo Ubaghs, CFO of Frontier Medicines. Gerardo has had one of the most unique career journeys you’ll hear — from being a professional violinist, to working in investment banking, and then stepping into biotech where he’s helped build and finance some of the most innovative...

Welcome back to another episode of The Bio Hub, we were delighted to be joined by two leaders from Shinobi Therapeutics, a company pushing the boundaries of off-the-shelf cell therapy through an innovative stealth cell platform that aims to overcome immune rejection and unlock the full potential of allogeneic CAR-T and CAR-NK therapies."With us is Dr. Dan Kemp, CEO of Shinobi Therapeutics. Da...

From BIO Boston: Alex Blyth, CEO of LifT Biosciences In this powerful opening episode from BIO 2025, I sit down with Alex Blyth, the founder and CEO of LifT Biosciences — a company re-engineering the immune system to finally beat cancer at its own game. We talk about: Why targeted therapies are failing most patients What tumour escape is and why it’s the real enemy How LiFt’s “super neutrophils” c...

Welcome to another episode of The Bio Hub. We were thrilled to welcome Jaideep Dudani, Founding CEO of Ouro Medicines and Portfolio Principal at Monograph Capital. Jaideep holds a PhD from MIT and a BS in Bioengineering from UCLA. Jaideep began his career at Vida Ventures and played key R&D, strategy, and business development roles at Relay Therapeutics. Jaideep later helped launch Human Immun...

So welcome back to another episode of the Bio Hub, we were delighted to welcome Alec Ford (CEO of Karius) and Stacy Solorio (Chief people Officer at Karius). Alec is a veteran of the genomics and biotech industries with over 30 years of leadership experience. Alec is leading the charge in transforming infectious disease diagnostics through Karius’s groundbreaking liquid biopsy test, which uses mic...

We were delighted to welcome Dr. Dan Williams, CEO and co-founder of SynaptixBio, a pioneering biotech company on a mission to develop life-changing treatments for children affected by devastating brain disorders, onto the bio hub. With over two decades of experience in the biotech and pharmaceutical industries, Dan has led teams from the lab bench to global clinical programs, and now he’s tacklin...

We were delighted to welcome Adam Thomas, Chief People & Experience Officer at MOMA Therapeutics onto the Bio Hub, where he brings over two decades of strategic HR leadership across the biotech, pharmaceutical, and consumer industries. Since joining MOMA in 2024, Adam has led the company’s people and culture strategy during its pivotal transition into a clinical-stage organization, focusing on...

From BIO Boston: Eamonn Hobbs, CEO of Syncromune Eamonn Hobbs is a biotech veteran and serial CEO — and in this episode, he shares how Syncromune is rewriting the playbook for immunotherapy. We talk about: – How Syncromune’s SYNC-T platform delivered 87% ORR and 53% CR in mCRPC– What it means to synchronize drug, device, and immune response– Raising one of the few $100M Series A rounds in 2024– Th...

From BIO Boston: Spike Lo, VP of Business Development at AP Biosciences In this episode, I sit down with Spike Lo — a seasoned BD leader helping take AP Biosciences global. We dive into: — The rise of AP and their $96M raised to date— How their CD137-based T-cell engager platform is built for safety and precision— What sets Taiwan’s biotech ecosystem apart— Spike’s mindset on resilience, urgency,...

Josh Mandel-Brehm, CEO of CAMP4 Therapeutics In this episode, I sit down with Josh Mandel-Brehm, the CEO of CAMP4 — a company pioneering a completely new approach in RNA therapeutics: upregulating gene expression using antisense oligonucleotides (ASOs). Josh shares the journey from a 5-person team to a publicly traded company, and how CAMP4’s platform is unlocking treatment for diseases previously...

From BIO Boston: Jan Thirkettle, CEO of Harness Therapeutics In this episode, I sit down with Jan Thirkettle, a biotech leader with deep experience across gene therapy, platform innovation, and company-building. Jan was part of the team that helped bring one of the first ex vivo gene therapies to market. Today, he’s leading Harness Therapeutics — a UK-based company developing a novel class of RNA...